pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

487 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1867Endpoints1449Fierce Biotech765BioSpace757BioPharma Dive548raps249onclive165fda recalls120
therapy area
allOncology12909Rare Disease3338Immunology3024Cardiology2848Hematology2298Pulmonology2255Vaccines1854
  • EU regulators and industry discuss streamlining combination product oversight at summit
    At the AFDO/RAPS Combination Products Summit, a panel of European regulators and industry representatives met to explore ways to simplify the regulatory pathway for combination products in the EU.…
    raps · 2d agoRegulatoryNeutral↗ source
  • FDA releases new manual outlining clinical pharmacology review practices for NDAs and BLAs
    The U.S. Food and Drug Administration’s Office of Translational Sciences and Office of Clinical Pharmacology have issued a new manual of procedures and policies (MAPP).\n\nThe document sets out goo…
    raps · 2d agoRegulatoryNeutral↗ source
← prev
page 1 of 20
next →
fda medwatch115
globenewswire health73
fda press62
Psychiatry & CNS1230
Ophthalmology1133
Endocrinology & Metabolism807
Pain791
Nephrology785
  • FDA to call AI "super intelligence" in all official communications
    The FDA announced that it will replace the term "artificial intelligence" with "super intelligence" in its official materials. The change applies to all correspondence, public communications, webs…
    raps · 2d agoRegulatoryNeutral↗ source
  • Recon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple Bio
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 2d ago↗ source
  • FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissioner
    The FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…
    raps · 3d agoRegulatoryNeutral↗ source
  • Industry groups push for clearer FDA guidance on ANDA and 505(b)(2) filings amid rising patent thickets
    Industry trade groups representing brand‑name and generic manufacturers have asked the FDA to clarify its recent guidance on when a company should file an abbreviated new drug application (ANDA) ve…
    raps · 3d agoRegulatoryNeutral↗ source
  • Experts discuss AI applications and challenges in regulatory conformity assessments
    At a recent RAPS AI in Regulatory Conference in Barcelona, a panel of experts examined how artificial intelligence is being adopted in conformity assessment processes. Participants noted that noti…
    raps · 3d agoRegulatoryNeutral↗ source
  • Australian regulator seeks feedback on adding unique device IDs to medical device free‑sale certificates
    Australia’s Therapeutic Goods Administration (TGA) announced it is reviewing whether to include unique device identification (UDI) details on certificates of free sale that accompany medical device…
    raps · 3d agoRegulatoryNeutral↗ source
  • FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapses
    The U.S. Food and Drug Administration sent warning letters to three manufacturers of active pharmaceutical ingredients (APIs) based in China. Two of the companies were cited for refusing to provid…
    raps · 6d agoRegulatoryNegative↗ source
  • FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapses
    The FDA sent warning letters to three active pharmaceutical ingredient manufacturers based in China. Two firms were cited for refusing the agency's requests for records, while the third was found…
    raps · 6d agoRegulatoryNeutral↗ source
  • FDA pauses voucher program as Eli Lilly's GLP-1 weight-loss drug cleared in China; experts see AI aid for device regulation
    The U.S. Food and Drug Administration announced it is shelving the commissioner's voucher program, effectively pausing the incentive that speeds up review of certain products. Eli Lilly secured ap…
    raps · 7d agoRegulatoryNeutral↗ source
  • EMA seeks industry input on draft guideline for biomarker-guided therapy approvals
    The European Medicines Agency has published a draft guideline that details the information required for approving medicines that use biomarkers to select patients. The agency is opening a public c…
    raps · 7d agoRegulatoryNeutral↗ source
  • FDA asks industry for feedback on improving patient-level real-world data submissions
    The FDA announced a request for comments on ways to address challenges associated with submitting patient-level real-world data and evidence in drug and biologic applications. The agency is seekin…
    raps · 7d agoRegulatoryNeutral↗ source
  • Specialized AI tools could streamline medical device regulatory work, experts say, but need expert oversight
    At a recent RAPS AI in Regulatory conference in Barcelona, a panel of experts discussed the role of specialized artificial intelligence in meeting regulatory requirements for medical devices. They…
    raps · 7d agoRegulatoryNeutral↗ source
  • FDA releases draft guidance for early-phase first-in-human studies of solid-tumor therapies
    The U.S. Food and Drug Administration has issued draft guidance to help sponsors design early-phase first-in-human IND studies for investigational drugs and biologics targeting solid tumors. The g…
    raps · 8d agoRegulatoryNeutral↗ source
  • Acting FDA commissioner reports strong public interest in new expedited IND pilot
    Acting FDA Commissioner Kyle Diamantas told attendees at the Friends of Cancer Research annual meeting that the agency’s newly launched Expedited IND pilot has attracted considerable public attenti…
    raps · 9d agoRegulatoryPositive↗ source
  • Experts urge pharma firms to build regulatory intelligence before laws take effect
    Regulatory specialists advise companies not to wait for legislation to be finalized before creating a regulatory intelligence framework. They argue that early preparation helps firms stay ahead of…
    raps · 9d agoRegulatoryNeutral↗ source
  • Recon: Bayer wins FDA approval for stroke prevention drug; Third Rock enters $2B partnership with AI-focused Chinese biotech
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 9d ago↗ source
  • India moves to suspend licenses of firms making substandard medicines
    The Indian government has proposed a rule that would immediately suspend the manufacturing licence of any company whose drug fails to meet quality standards. The initiative is intended to boost dr…
    raps · 10d agoRegulatoryNeutral↗ source
  • FDA cuts required analytical tests for emergency-use diagnostic devices in new guidance
    On 9 November 2026 the U.S. Food and Drug Administration released final guidance aimed at simplifying validation of in-vitro diagnostic devices used in public-health emergencies. The document outli…
    raps · 10d agoRegulatoryPositive↗ source
  • FDA reduces required analytical tests for emergency-use diagnostic devices
    The FDA finalized new guidance aimed at streamlining validation for in-vitro diagnostic (IVD) devices that detect emerging pathogens during public-health emergencies. The guidance lowers the numbe…
    raps · 10d agoRegulatoryNeutral↗ source
  • Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 10d ago↗ source
  • Regulators urge risk-based lifecycle approach for AI tools amid election-linked FDA uncertainty
    A panel of regulatory experts at the RAPS AI in Regulatory Conference in Barcelona urged professionals using AI tools to adopt a risk-based, life-cycle perspective rather than focusing solely on va…
    raps · 13d agoRegulatoryNeutral↗ source
  • Regulatory experts urge risk-based, lifecycle validation for AI tools in FDA work
    At the RAPS AI in Regulatory Conference in Barcelona, a panel of experts discussed the growing use of AI tools by regulatory professionals. They recommended a risk-based, lifecycle approach to val…
    raps · 13d agoRegulatoryNeutral↗ source
  • MDCG issues guidance on clinical evidence for orphan in-vitro diagnostics
    The Medical Device Coordination Group (MDCG) has published new guidance that explains how clinical evidence requirements apply to orphan in-vitro diagnostics (IVDs). The document is intended to he…
    raps · 14d agoRegulatoryNeutral↗ source